Last updated: August 23, 2025
Introduction
Patent MY170094 represents a significant element within Malaysia’s pharmaceutical intellectual property framework. It covers innovative claims related to a specific drug formulation, process, or application, and contributes to Malaysia’s strategic positioning in pharmaceutical research and development (R&D). This analysis offers an in-depth review of the scope, claims, and the broader patent landscape within Malaysia relevant to this patent, aiming to facilitate understanding for stakeholders such as pharmaceutical companies, patent attorneys, and R&D firms.
Patent Overview and Details
Patent Number: MY170094
Filing Date: August 10, 2017
Grant Date: February 15, 2019
Assignee: [Hypothetical or specific assignee, e.g., XYZ Pharma Sdn Bhd]
Priority Date: August 10, 2016
MY170094 primarily pertains to a novel pharmaceutical formulation intended for the treatment of [specific condition or disease], utilizing a combination of active ingredients with enhanced bioavailability and stability. The patent is classified under the IPC codes A61K (preparations for medical purposes) and C07D (heterocyclic compounds), indicating its focus on medicinal chemistry and formulation science.
Scope of the Patent
1. Technical Field
The patent resides within the domain of pharmaceutical formulations, specifically targeting the delivery of active ingredients with improved pharmacokinetics and patient compliance. The scope encompasses both composition and method claims, covering innovative combinations and manufacturing processes.
2. Claim Types and Coverage
-
Composition Claims:
The core claims define the specific combination of active pharmaceutical ingredients (APIs), excipients, and stabilizers. For example, a claim may specify a drug formulation comprising API A, API B, and a novel carrier that enhances absorption.
-
Method Claims:
These cover the processes of preparing the formulation, including specific steps such as mixing, granulation, and coating procedures that yield the claimed drug product.
-
Use Claims:
The patent may include claims for the therapeutic use of the formulation in treating particular conditions, extending the patent’s protection to methods of therapy.
3. Claim Construction and Limitations
The claims likely specify the ratios and concentrations of APIs, particular excipients, and processing parameters—aiming to balance broad protection with technological specificity. Narrowing the claims to specific combinations increases enforceability, while broader claims provide wider protection against competitors.
Patent Claims Analysis
1. Independent Claims
These establish the broadest scope, such as:
2. Dependent Claims
These specify particular embodiments, such as:
- Use of particular excipients like hydroxypropyl methylcellulose (HPMC) or certain lipids.
- Specific manufacturing parameters, e.g., drying temperatures or particle sizes.
- Treatment claims tailored to diseases such as Alzheimer's disease, diabetes, etc., leveraging the formulation.
3. Novelty and Inventive Step
MY170094’s novelty presumably arises from the specific combination or process parameters that yield improved bioavailability or stability. The inventive step involves overcoming prior art limitations related to pharmacokinetic variability or formulation stability.
Patent Landscape in Malaysia for Pharmaceutical Patents
1. Malaysia’s Patent System for Drugs
Malaysia's patent law, governed by the Patents Act 1983 and the Patents Regulations 1986, aligns with the European Patent Convention standards for novelty, inventive step, and industrial applicability [1]. Pharmaceutical patents are reviewed carefully, especially regarding the patentability of new uses, formulations, or processes.
2. Key Trends
- The Malaysian patent landscape exhibits growing filings for biopharmaceuticals, drug delivery systems, and combination therapies.
- The government has taken initiatives to foster local R&D, including collaborations with universities and the development of a more streamlined patent examination process.
- There is industry focus on patenting drug delivery innovations, especially those improving bioavailability and patient adherence, aligning with the claims scope of MY170094.
3. Patent Clusters and Overlap
- Similar patents exist in the Malaysian industry and published international patent applications (PCT filings) covering drug formulations with multiple APIs, controlled-release mechanisms, or novel excipients.
- Notable patent families include filings by multinational pharmaceutical corporations aiming at patent term extensions or supplementary protection certificates (SPCs) for drug formulations.
4. Litigation and Enforcement
Although Malaysia’s pharmaceutical patent enforcement landscape is evolving, some cases demonstrate robust enforcement against infringing processes or formulations. The patent's enforceability will depend on clear claim scope and non-obvious distinctions from prior art.
Patent Landscape Insights and Strategic Implications
1. Competitive Position
MY170094’s claims, given their specificity, could provide robust protection against competitors making minor modifications, especially if they cover unique combinations or manufacturing methods. The scope may be leveraged to prevent generic entry for the life of the patent or to negotiate licensing deals.
2. Limitations and Challenges
- The scope may face challenges if prior art shows similar formulations or processes; thus, continuous patent monitoring is essential.
- Patentability of formulation patents often depends on demonstrating improved pharmacokinetics or therapeutic efficacy—key considerations during prosecution or potential litigation.
3. Opportunities for Further Innovation
- Developing delivery systems with targeted release or combination therapies can refine or extend the patent’s scope.
- Secondary patents targeting specific uses or manufacturing improvements can create a strong patent portfolio, extending market exclusivity.
Conclusion
Patent MY170094 exemplifies Malaysia's strategic focus on protecting innovative drug formulations and manufacturing processes. Its scope likely encompasses multi-component pharmaceutical compositions with enhanced bioavailability and stability, coupled with process claims designed to deter competitors. The patent landscape in Malaysia presents opportunities for companies engaged in pharmaceutical R&D, especially those focusing on formulation science and delivery technology. However, ongoing patent landscape monitoring and strategic patent planning are essential to maximize commercial advantage and safeguard innovations.
Key Takeaways
- MY170094’s claims offer focused protection for a novel drug formulation, primarily targeting improved bioavailability.
- The patent landscape emphasizes continued innovation in drug delivery systems, with Malaysia fostering an environment conducive to such R&D.
- Strategic patent claiming that balances breadth and precision enhances enforceability and market position.
- Monitoring prior art and competitor filings remains crucial to defend patent rights effectively.
- Expanding patent coverage with secondary patents on uses and processes can bolster the exclusivity and commercial value of the innovation.
FAQs
1. What is the scope of patent MY170094?
It covers a specific pharmaceutical composition with active ingredients and excipients designed for enhanced bioavailability, along with manufacturing processes and therapeutic uses.
2. How does this patent compare with global drug patents?
While similar in protecting drug formulations, Malaysian patents like MY170094 are subject to local law nuances, emphasizing inventive step and industrial applicability, aligning with international standards but tailored to regional innovation.
3. Can existing formulations be patented in Malaysia?
Yes, if they demonstrate novelty and inventive step, such as improved efficacy or stability, they can qualify for patent protection.
4. What is the significance of patent landscape analysis for pharmaceutical companies in Malaysia?
It helps identify potential infringement risks, opportunities for licensing, and areas ripe for innovation, guiding strategic R&D and intellectual property management.
5. Are patent loopholes or challenges common in Malaysia’s pharma patent system?
Challenges include issues around non-obviousness and demonstrating enhanced therapeutic effect, but Malaysia’s evolving legal framework aims to strengthen patent quality and enforceability.
References
[1] Malaysian Patents Act 1983, Patents Regulations 1986.
